Evidence map›Paper›PMID 40243655›Full record

ArticleInternational journal of molecular sciences2025

Nidogen-1, a Player in KMT2A-Rearranged Pediatric Acute Myeloid Leukemia.

Jolien Vanhooren, Larissa Deneweth, Luca Pagliaro, Zhiyao Ren, Mariateresa Giaimo, Rafaella Zamponi, Giovanni Roti, Barbara Depreter, Mattias Hofmans, Barbara De Moerloose and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. The Role ofBiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jolien VanhoorenDepartment of Internal Medicine and Pediatrics, Ghent University, 9000 Ghent, Belgium.ORCID 0000-0002-2604-0727
Larissa DenewethDepartment of Internal Medicine and Pediatrics, Ghent University, 9000 Ghent, Belgium.
Luca PagliaroTranslational Hematology and Chemogenomics (THEC), University of Parma, 43121 Parma, Italy.ORCID 0000-0001-5500-3522
Zhiyao RenDepartment of Internal Medicine and Pediatrics, Ghent University, 9000 Ghent, Belgium.ORCID 0000-0002-7598-9584
Mariateresa GiaimoTranslational Hematology and Chemogenomics (THEC), University of Parma, 43121 Parma, Italy.ORCID 0000-0002-8748-7012
Rafaella ZamponiTranslational Hematology and Chemogenomics (THEC), University of Parma, 43121 Parma, Italy.ORCID 0000-0002-3313-1387
Giovanni RotiTranslational Hematology and Chemogenomics (THEC), University of Parma, 43121 Parma, Italy.
Barbara DepreterDepartment of Laboratory Medicine, AZ Delta General Hospital, 8800 Roeselare, Belgium.
Mattias HofmansCancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium.
Barbara De MoerlooseDepartment of Internal Medicine and Pediatrics, Ghent University, 9000 Ghent, Belgium.
Tim LammensDepartment of Internal Medicine and Pediatrics, Ghent University, 9000 Ghent, Belgium.ORCID 0000-0001-8733-4027

Funding

Kom Op Tegen Kanker Grant To TLMETOYOU foundation grant to JVvzw Kinderkankerfonds grant to TL and BDM
6 · The paper itself

Abstract

Despite advances in outcome, one third of children with acute myeloid leukemia (AML) relapse, and less than half will achieve long-term survival. Relapse in AML has been shown to be driven in part by leukemic stem cells (LSCs), highlighting the unmet medical need to better characterize and target this therapy-resistant cell population. Micro-array profiling of pediatric AML subpopulations (LSCs and leukemic myeloblasts) and their healthy counterparts revealed

Indexed as

Gene RearrangementHistone-Lysine N-MethyltransferaseLeukemia, Myeloid, AcuteMyeloid-Lymphoid Leukemia ProteinAdolescentChildChild, PreschoolFemaleGene Expression Regulation, LeukemicHumansInfantMaleNeoplastic Stem CellsHistone-Lysine N-MethyltransferaseKMT2A protein, humanMyeloid-Lymphoid Leukemia ProteinAMLleukemic stem cellnidogen-1

Identifiers

PMID40243655
PMCPMC11988693

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.